Psychedelic Spotlight

In this day and age of spiritual tourism, traveling to a psychedelic retreat in Mexico, Jamaica or Peru has become a trendy new habit for explorers of altered states or for those in deep need of a mental health reset.

It’s been a high-profile year for ketamine. A variety of research studies have investigated how this dissociative can help address many of life’s challenges, including marital problems to treating psychiatric disorders such as depression, and even leading a billion-dollar empire. While most may be aware that ketamine is a general anesthetic, the substance is also used off-label in diverse medical scenarios.

In a world brimming with pharmaceutical options and synthetic remedies, natural alternatives have begun to be given more attention. One such option is Kanna (Sceletium tortuosum), a succulent plant native to South Africa. In this article, we delve into the captivating world of Kanna effects and uncover its wide array of potential benefits by examining the research that currently exists.

Psychedelic research is flourishing again, and mainstream Americans may soon feel its impact. MDMA is near the regulatory finish line thanks to MAPS’s recent new drug application submission. And psilocybin is not far behind. 2023 psychedelic research success means psilocybin could be legal therapeutically in a few short years. The latest studies show that 12 to 25 mg psilocybin doses for depression is sufficient for most patients.

This week, researchers published a study in Cancer, a journal of the American Cancer Society, evaluating the safety, feasibility, and efficacy of psilocybin-assisted group therapy for the treatment of major depressive disorder (MDD) in patients diagnosed with cancer in a Phase 2 open-label clinical trial. The researchers recruited 30 MDD patients with curable and non-curable cancer and administered a single 25 mg dose of psilocybin, with 3–4 patients receiving their dose simultaneously.

Last Friday, the Los Angeles Medical Examiner’s Office released the autopsy report associated with Matthew Perry, star of the 90’s sitcom, “Friends,” and who was tragically found dead in his Pacific Palisades pool on October 28. According to the report, it was determined that Perry’s cause of death was a result of “acute effects of ketamine” and subsequent drowning with levels of 3271-3540 ng/ml of ketamine present in his system at or around the time of death.

Mushroom chocolate bars are an obvious culinary choice. But a powerful pair lies beyond the incredible flavor. Research indicates that chocolate can synergize with psilocybin to enhance the psychedelic experience. This article explores mushroom chocolate benefits and explains how to make a magic mushroom chocolate bar for a full-spectrum journey. When you make a mushroom chocolate bar, you tap into an incredible synergy between chocolate and psilocybin.

Ready to step outside the box and embrace the unconventional? This year's holiday gift guide celebrates psychedelics and nods to those who appreciate the profound and the extraordinary. From thought-provoking reads to journals that capture the essence of mind-bending trips, this selection speaks directly to soul-seekers and plant lovers. Explore energizing culinary experiences. Consider skincare with an adaptogenic twist. Optimize your loved one’s health with nootropics.

Provincetown is a traditionally Portuguese community where LGBTQ people from around the world visit in search of community and healing. Now the select board of the town has opened up a new opportunity for the winter season when tourism wanes: psilocybin mushrooms. Categorized as a “breakthrough therapy” for depression by the FDA, psilocybin mushrooms and other psychedelic plants will now be the lowest priority for law enforcement in the community by order of the select board.

On December 12, MAPS Public Benefit Corporation announced their submission of New Drug Application (NDA) to the FDA for their MDMA-assisted therapy for PTSD program, marking a historic moment for the mental health field. This is a significant milestone for the psychedelics industry.